


LISTING AND AMENDMENT OF THE CLAIMS

1. (original) A pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:



wherein:

R<sub>1</sub> represents methoxy, ethoxy or hydroxy;

R<sub>2</sub> represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,

or a pharmacologically acceptable solvate thereof.

2. (original) A pamoate salt as claimed in Claim 1, wherein R<sub>1</sub> represents methoxy and R<sub>2</sub> represents methoxy or hydrogen.


3. (original) A pamoate salt as claimed in Claim 2, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

4. (original) A pamoate salt as claimed in Claim 2, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

5. (currently amended) A pamoate salt as claimed in ~~any one of the preceding claims~~ Claim 1, wherein the pamoate salt is in the form of its (-) isomer.

6. (currently amended) A pamoate salt as claimed in ~~any one of the preceding claims~~ Claim 1, wherein the pamoate salt is in the form of a hydrate.

7. (original) A pharmaceutical composition comprising a pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:



wherein:

$R_1$  represents methoxy, ethoxy or hydroxy;

$R_2$  represents methoxy, ethoxy, hydroxy or hydrogen; and

$n$  represents 2 or 3,

or a pharmacologically acceptable solvate thereof

and a pharmacologically acceptable diluent or carrier.


8. (original) A pharmaceutical composition as claimed in Claim 7 for the treatment or prophylaxis of a stress-related affective disorder.

9. (currently amended) A pharmaceutical composition as claimed in Claim 7 ~~or Claim 8~~, wherein the 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione ~~is as defined in any one of Claims 2, 5 and 6~~ has the Formula (I) wherein  $R_1$  represents methoxy and  $R_2$  represents methoxy or hydrogen and/or wherein the pamoate salt is in the form of its (-) isomer and/or wherein the pamoate salt is in the form of its hydrate.

10. (original) A pharmaceutical composition as claimed in Claim 9, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

11. (original) A pharmaceutical composition as claimed in Claim 9, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

12. (original) A pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:



wherein:

R<sub>1</sub> represents methoxy, ethoxy or hydroxy;

R<sub>2</sub> represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,


or a pharmacologically acceptable solvate thereof

for use in treatment of the human or animal body by therapy or diagnosis practised on the human or animal body.

13. (presently amended) A pamoate salt as claimed in Claim 12, wherein the 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione ~~is as defined in any one of Claims 2, 5 and 6~~ has the Formula (I) wherein R<sub>1</sub> represents methoxy and R<sub>2</sub> represents methoxy or hydrogen and/or wherein the pamoate salt is in the form of its (-) isomer and/or wherein the pamoate salt is in the form of its hydrate.

Claims 16-24 (canceled).

25. (original) A method for the treatment or prophylaxis of a stress-related affective disorder which comprises administering to a human or animal patient an effective amount of a pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:



wherein:

R<sub>1</sub> represents methoxy, ethoxy or hydroxy;

R<sub>2</sub> represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,

or a pharmacologically acceptable solvate thereof.

26. (original) A method as claimed in Claim 25, wherein the stress-related affective disorder is selected from the group consisting of agoraphobia; anorexia nervosa; anxiety; anxiogenesis associated with withdrawal from drugs of abuse; bulimia nervosa; chronic paroxysmal hemicrania; depression (including prevention of depressive recurrences); diminution of the immune response associated with anxiety, depression or bereavement; disorders of sleep initiation or maintenance; disorders of the sleep-awake schedule; dream anxiety attacks; Huntington's chorea; Kleine-Levin syndrome; memory disturbance; Ménière's disease, menstrual-associated sleep syndrome; migraine; motion sickness; nausea incompletely relieved by 5HT<sub>3</sub> antagonist administration, neurogenic pain; neuropathic pain; obsessive-compulsive disorder; panic attacks; posttraumatic stress disorder; pre-menstrual dysphoric disorder; recurrent brief depression; Restless Leg syndrome, schizophrenia; senile dementia; serotonin-irritation syndrome; sleep apnoea; sleep related cardiovascular symptoms; sleep related epileptic seizures; sleep-related cluster headaches; sleep-related myoclonus syndrome; social phobia; sudden infant death syndrome; and tinnitus.

27. (original) A method as claimed in Claim 26, wherein the stress-related affective disorder is anxiety.

28. (original) A method as claimed in Claim 26, wherein the stress-related affective disorder is depression.

29. (original) A method as claimed in Claim 26, wherein the stress-related affective disorder is migraine.

30. (original) A method as claimed in Claim 26, wherein the stress-related affective disorder is sleep apnoea.

31. (currently amended) A method as claimed in ~~any one of Claims 25 to 30~~, wherein ~~the 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione is as defined in any one of Claims 2, 5 and 6~~ R<sub>1</sub> represents methoxy and R<sub>2</sub> represents methoxy or hydrogen and/or wherein the pamoate salt is in the form of its (-) isomer and/or wherein the pamoate salt is in the form of a hydrate.

32. (original) A method as claimed in Claim 31, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

33. (original) A method as claimed in Claim 31, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.